Articles
Reimplantation of cryopreserved ovarian tissue, a technique that has been used successfully in women with lymphoma or solid tumors, may cause disease recurrence in women with leukemia, a new study indicates.
Reduced-intensity therapy may be just as effective but less toxic than a more intense regimen for patients with early-stage Hodgkin’s lymphoma, German researchers report.
Four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by 30 Gy of involved-field radiation therapy is widely regarded as the standard of care for patients with early-stage Hodgkin’s lymphoma with a favorable prognosis.
Read More ›By Wayne Kuznar
CHICAGO—A fentanyl pectin nasal spray provides analgesia faster than immediate-release morphine in the treatment of breakthrough cancer pain, said Andrew Davies, MD, MSc at the 46th American Society of Clinical Oncology annual meeting.
Breakthrough cancer pain is a transient exacerbation of pain that occurs despite relatively stable and adequately controlled background pain and has a significant impact on quality of life.
By Wayne Kuznar
CHICAGO—A risk stratification schema can be used to identify older patients who are at risk of grade-3 to -5 toxicity from chemotherapy. The schema includes risk factors based on cancer type, patient age, upfront dose of chemotherapy, the chemotherapeutic regimen used, and history of falling, among others, said Arti Hurria, MD at the 46th American Society of Clinical Oncology annual meeting.
“We wanted to develop a predictive model for tolerance to therapy in older adults with cancer,” she said.
By Wayne Kuznar
CHICAGO—Bevacizumab in combination with chemotherapy followed by maintenance bevacizumab monotherapy improves progression-free survival (PFS) over chemotherapy alone in the treatment of advanced ovarian cancers, said Robert A. Burger, MD at the 46th American Society of Clinical Oncology annual meeting.
By Wayne Kuznar
CHICAGO—Denosumab delayed or prevented more skeletal-related adverse events than zoledronic acid in men with hormone-refractory prostate cancer and bone metastases.
The superior efficacy of denosumab on this end point along with its ease of administration—subcutaneous rather than intravenous—gives it an edge over zoledronic acid, said Karim Fizazi, MD, PhD, lead investigator of a study comparing the two treatments, at the 46th American Society of Clinical Oncology annual meeting.
By Wayne Kuznar
CHICAGO—Twice-daily dosing of naproxen can reduce the incidence and severity of bone pain in cancer patients being treated with pegfilgrastim, according to data presented at the 2010 annual meeting of the American Society of Clinical Oncology.
CHICAGO—In a phase 1 study in advanced non–small-cell lung cancer (NSCLC) deemed worthy of a presentation at the American Society of Clinical Oncology’s 46th annual meeting plenary session, a multinational group of investigators reported improved survival with an oral investigational agent still unfamiliar to most oncologists.
Researchers at Rutgers, the State University of New Jersey, report that they have achieved greater than 90% accuracy in distinguishing high-grade from low-grade prostate cancers using computer analysis of magnetic resonance (MR) images and spectra of the patient’s prostate gland. The findings may help determine which patients need aggressive treatment and which may be better served by watchful waiting.
The use of oral bisphosphonates was not found to be significantly associated with incident esophageal or gastric cancer, according to a retrospective analysis of patients from the UK General Practice Research Database. Based on their findings, Cardwell and colleagues concluded that, for patients in which they are clinically indicated, bisphosphonates should not be withheld solely on the basis of possible esophageal cancer risk.